Scarica l'app Stockscreener
15.05
0.07%
0.01
Dopo l'orario di chiusura:
15.16
0.11
+0.73%
Precedente Chiudi:
$15.04
Aprire:
$15.5
Volume 24 ore:
3.73M
Relative Volume:
1.64
Capitalizzazione di mercato:
$1.30B
Reddito:
$139.71M
Utile/perdita netta:
$-209.36M
Rapporto P/E:
-5.0845
EPS:
-2.96
Flusso di cassa netto:
$-160.60M
1 W Prestazione:
-7.10%
1M Prestazione:
+0.07%
6M Prestazione:
+36.20%
1 anno Prestazione:
-24.33%
Intervallo 1D:
$14.88
$16.04
Intervallo di 1 settimana:
$14.69
$16.48
Portata 52W:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Confronta SNDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
15.05 | 1.32B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-10 | Ripresa | Stifel | Buy |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
What analysts say about Syndax Pharmaceuticals Inc stockPrice Support Zones & Low Cost Capital Trading - earlytimes.in
Syndax Pharmaceuticals Inc. stock momentum explainedJuly 2025 PostEarnings & Detailed Earnings Play Strategies - newser.com
Syndax Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Breakouts & Safe Capital Growth Tips - newser.com
How risky is Syndax Pharmaceuticals Inc. stock nowTrade Ideas & Community Trade Idea Sharing - newser.com
Syndax Pharmaceuticals' (SNDX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
SNDX Receives 'Buy' Rating From HC Wainwright & Co. with $40 PT | SNDX Stock News - GuruFocus
Why Syndax Pharmaceuticals Inc. stock is rated strong buyTreasury Yields & Stepwise Trade Signal Guides - newser.com
Comparing Syndax Pharmaceuticals Inc. in custom built stock radarsWeekly Trend Recap & Free Risk Controlled Daily Trade Plans - newser.com
Tick level data insight on Syndax Pharmaceuticals Inc. volatilityMarket Activity Summary & Breakout Confirmation Trade Signals - newser.com
Is Syndax Pharmaceuticals Inc. (1T3) stock considered safe havenStop Loss & Verified Stock Trade Ideas - newser.com
Published on: 2025-10-15 03:14:39 - newser.com
Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Path To Profitability - 富途牛牛
Technical analysis overview for Syndax Pharmaceuticals Inc. stock2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.9%Here's What Happened - MarketBeat
Real time pattern detection on Syndax Pharmaceuticals Inc. stockJuly 2025 Price Swings & Fast Entry Momentum Trade Alerts - newser.com
Heatmap analysis for Syndax Pharmaceuticals Inc. and competitors2025 EndofYear Setup & AI Driven Stock Movement Reports - newser.com
Evaluating Syndax Pharmaceuticals Inc. with trendline analysis2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Order flow analysis tools used on Syndax Pharmaceuticals Inc.July 2025 Action & Pattern Based Trade Signal System - newser.com
Will Syndax Pharmaceuticals Inc. stock see insider buying2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
Published on: 2025-10-10 04:00:50 - newser.com
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - GlobeNewswire Inc.
Syndax resumed with Buy at Stifel on newly launched drugs - MSN
Analyzing drawdowns of Syndax Pharmaceuticals Inc. with statistical toolsPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Published on: 2025-10-09 05:04:06 - newser.com
Should you hold or exit Syndax Pharmaceuticals Inc. nowJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Is Syndax Pharmaceuticals Inc 1T3 a good long term investmentValue Traps to Avoid & Small Investment Portfolio - earlytimes.in
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Research Analysts Offer Predictions for SNDX FY2027 Earnings - MarketBeat
Will October's FDA Decision Be A Shot In The Arm For Revuforj's Expansion? - RTTNews
Measuring Syndax Pharmaceuticals Inc.’s beta against major indices2025 Geopolitical Influence & Reliable Volume Spike Alerts - newser.com
Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision - Yahoo Finance
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
BRIEF-Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - The Sunday Guardian
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule - MarketScreener
Does Syndax Pharmaceuticals Inc. qualify in momentum factor screeningStop Loss & Daily Entry Point Trade Alerts - newser.com
Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals - MSN
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Syndax Pharmaceuticals Inc Azioni (SNDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer |
Sep 08 '25 |
Sale |
16.41 |
157,307 |
2,582,021 |
298,661 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):